Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLEDYL vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular c AMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of bronchial asthma,Treatment of reversible bronchospasm associated with chronic bronchitis and emphysema
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
40% bound, primarily to albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
Vd: 0.5 L/kg (0.3-0.7 L/kg); clinical meaning: distributes into total body water, with higher volume in premature neonates.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 100%; oral sustained-release: 85-95%; rectal: 90-100% (variable).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: administer 200 mg every 12-24 hours; consider monitoring serum theophylline levels.
No data; not applicable.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: contraindicated or reduce dose by 90% with close monitoring of serum levels.
No data; not applicable.
Not recommended for children under 6 years; for children 6-12 years: 10-12 mg/kg/day divided every 6-8 hours; for adolescents: same as adult dosing, adjusted based on serum levels.
No data; not applicable.
Start at 200 mg twice daily; adjust based on serum theophylline levels (target 5-15 mcg/m L); monitor for toxicity due to reduced clearance.
No data; not applicable.
No FDA black box warning.
None
Risk of toxicity due to narrow therapeutic index; serum levels should be monitored carefully.,Use with caution in patients with peptic ulcer, cardiac arrhythmias, seizure disorders, or hyperthyroidism.,May exacerbate gastroesophageal reflux disease.,Concomitant use with other xanthine derivatives may increase toxicity.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or choline salicylate,Active peptic ulcer disease,Seizure disorder (unless appropriately controlled)
Hypersensitivity to arformoterol or any component of the formulation
High-fat meals may increase absorption; avoid charbroiled meats which decrease theophylline clearance. Consistent caffeine intake should be maintained to avoid fluctuations in drug levels.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Choledyl (theophylline oxtriphylline) is a xanthine derivative. In pregnancy, theophylline crosses the placenta. First trimester: No consistent evidence of major malformations, but some studies suggest a small increased risk of congenital heart defects. Second and third trimesters: Fetal tachycardia, jitteriness, and hypoglycemia can occur with maternal high levels. Neonatal withdrawal and respiratory distress have been reported.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk. Milk-to-plasma ratio is approximately 0.6-0.7. Concentrations in milk can reach 60-70% of maternal serum levels. Infant exposure may cause irritability, jitteriness, and poor feeding. Use with caution, monitor infant for adverse effects, and consider timing doses after breastfeeding.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
During pregnancy, theophylline clearance may decrease due to reduced hepatic metabolism and increased plasma volume. Dose adjustments are often required, especially in the third trimester. Monitor serum levels closely, as clearance can decrease by 20-30%. Dose may need to be reduced by 20-30% to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels, requiring dose increase.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Choledyl (oxtriphylline) is a bronchodilator; monitor theophylline levels due to narrow therapeutic index. Avoid in patients with peptic ulcer or seizure disorders. Cautious use with hepatic impairment or heart failure. Dose adjustment needed with cimetidine, ciprofloxacin, or macrolides due to decreased clearance.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take with food if GI upset occurs.,Avoid excessive caffeine (coffee, tea, cola) as it may increase side effects.,Do not crush or chew sustained-release forms.,Seek medical attention for rapid heartbeat, seizures, or severe nausea.,Report signs of toxicity: persistent vomiting, confusion, or palpitations.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLEDYL vs AEROLONE, answered by our medical review team.
CHOLEDYL is a Bronchodilator that works by Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular c AMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLEDYL and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLEDYL is: 200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLEDYL and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLEDYL is classified as Category C. Choledyl (theophylline oxtriphylline) is a xanthine derivative. In pregnancy, theophylline crosses the placenta. First trimester: No consistent evidence of major malformations, but. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.